Journal article
Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study
T Porter, SC Burnham, L Milicic, G Savage, P Maruff, YY Lim, QX Li, D Ames, CL Masters, S Rainey-Smith, CC Rowe, O Salvado, D Groth, G Verdile, VL Villemagne, SM Laws
Journal of Alzheimer S Disease | IOS PRESS | Published : 2018
DOI: 10.3233/JAD-180713
Abstract
Background: With the exception of APOE, genetic variants associated with increased Alzheimer's disease (AD) risk are characterized by small effect sizes. Polygenic risk scores (PRS) have shown utility in predicting AD risk; however, their utility for predicting decline in cognition at preclinical stages of AD is poorly understood. Objective: To validate associations of a 22-variant AD-risk-weighted PRS with AD risk and related biomarkers and to assess its utility to predict cognitive decline. Methods: The PRS was evaluated with respect to brain amyloid-β (Aβ) burden, cerebrospinal fluid (CSF) Aβ 42, total-Tau, and phospho-Tau, and decline in cognition in 643 (570 cognitively normal (CN), 73 ..
View full abstractGrants
Funding Acknowledgements
Funding for the AIBL study was provided in part by the study partners [Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd.]. The AIBL study has also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as funding from the Science and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for Mental Health (Grant ID: 20100104), an Australian Government Initiative. We thank all those who took part as subjects in the study for their commitment and dedication to helping advance research into the early detection and causation of AD. We kindly thank all AIBL Research Group members (http://aibl.csiro.au/about/aibl-research-team/). All data and samples used in this study are derived from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. AIBL data can be accessed through an Expression of Interest procedure, for more information please see https://aibl.csiro.au/awd.